Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents
| Autor: | Aviva Joseph, Evgenia Greenbaum, Evelyne Zeira, Ilan Babai, Reinhard Glück, Eli Kedar, Zichria Zakay-Rones, Arie Ben-Yehuda, Igal Louria-Hayon, Ilia Galprin, Simcha Even-Chen, Yechezkel Barenholz, Rinaldo Zurbriggen |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
Quality Control Influenza vaccine Neuraminidase Hemagglutinin (influenza) Antibodies Viral Mice Adjuvants Immunologic Double-Blind Method Antigen Animals Humans Medicine Seroconversion Antigens Viral Phospholipids Aged Cell Nucleus Mice Inbred BALB C Hemagglutination assay General Veterinary General Immunology and Microbiology biology business.industry Immunogenicity Vaccination Public Health Environmental and Occupational Health Hemagglutination Inhibition Tests Virology Recombinant Proteins Nursing Homes Infectious Diseases Immunization Influenza Vaccines Antibody Formation Liposomes Immunology biology.protein Interleukin-2 Molecular Medicine Female business |
| Zdroj: | Vaccine. 21:3169-3178 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/s0264-410x(03)00251-2 |
| Popis: | Influenza and its complications account for substantial morbidity and mortality, especially among the elderly. In young adults, immunization provides 70-90% protection, while among the elderly the vaccine may be only/=50% effective; hence, the need for new, more immunogenic vaccines. We compared the safety and immunogenicity of a novel, interleukin-2 (IL-2) -supplemented trivalent liposomal influenza vaccine (designated INFLUSOME-VAC) with that of a commercial trivalent split virion vaccine in community-residing elderly volunteers (mean age 81 years) in winter of 2000/2001. Eighty-one individuals were randomly assigned to be vaccinated intramuscularly, either with the standard vaccine (n=33) or with INFLUSOME-VAC (n=48) prepared from the former. The two vaccines contained equal amounts of hemagglutinin (HA) ( approximately 15 microgram of each viral strain); INFLUSOME-VAC consisted of liposomal antigens admixed with liposomal human IL-2 (Lip IL-2) (33 microgram = 6x10(5) IU/dose). At 1 month post-vaccination, seroconversion rates (tested by hemagglutination inhibition) for the A/New Caledonia (H1N1) and A/Moscow (H3N2) strains were significantly higher (P=0.04) in the INFLUSOME-VAC group (65 versus 45%, 44 versus 24%, respectively). Moreover, INFLUSOME-VAC induced a greater anti-neuraminidase (NA-N2) response (P0.05). Anti-IL-2 antibodies were undetected, and no increase in anti-phospholipid IgG antibodies was found in the INFLUSOME-VAC group. Adverse reactions were similar in both groups. Thus, INFLUSOME-VAC appears to be both safe and more immunogenic than the currently used vaccine in the elderly. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect